Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levenson, R. M.
Right arrow Articles by Ihde, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levenson, R. M.
Right arrow Articles by Ihde, D. C.

Radiology, Vol 146, 513-518, Copyright © 1983 by Radiological Society of North America

ARTICLES

Comparative value of bone scintigraphy and radiography in monitoring tumor response in systemically treated prostatic carcinoma

RM Levenson, BJ Sauerbrunn, HR Bates, RD Newman, JL Eddy and DC Ihde

Radionuclide bone scans and skeletal radiographs were obtained before and during combination chemotherapy or initial hormonal treatment in 46 patients with disseminated adenocarcinoma of the prostate. The purpose of the study was to determine the usefulness of these two modalities in evaluating tumor response to therapy. Prior to treatment, bone scans were positive in 44 patients (96%). In all but one patient either bone radiographs or bone marrow biopsy revealed evidence of osseous metastases. In 22 patients partial response to therapy was documented by a variety of other staging tests. Eleven of these patients showed concurrent or later improvement on bone scans; one showed improvement on a radiograph. "Flare phenomena" were observed relatively frequently since 23% of the scans and 50% of the radiographs showed worsening at the time of response. Bone scans revealed worsening in 79% of 33 patients with disease progression of extraosseous tumor; radiographs were equally sensitive (82% worsening). It is concluded that bone scans in particular are useful for monitoring tumor status in systemically treated patients with prostate cancer. However, because of the lack of sensitivity for response and paradoxical worsening with tumor regression in some patients, scans are not accurate enough to be employed as the sole test in following these patients.


This article has been cited by other articles:


Home page
 JCOHome page
H. I. Scher, S. Halabi, I. Tannock, M. Morris, C. N. Sternberg, M. A. Carducci, M. A. Eisenberger, C. Higano, G. J. Bubley, R. Dreicer, et al.
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
J. Clin. Oncol., March 1, 2008; 26(7): 1148 - 1159.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Hamaoka, J. E. Madewell, D. A. Podoloff, G. N. Hortobagyi, and N. T. Ueno
Bone Imaging in Metastatic Breast Cancer
J. Clin. Oncol., July 15, 2004; 22(14): 2942 - 2953.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
W. M. Byun, S. O. Shin, Y. Chang, S. J. Lee, J. Finsterbusch, and J. Frahm
Diffusion-Weighted MR Imaging of Metastatic Disease of the Spine: Assessment of Response to Therapy
AJNR Am. J. Neuroradiol., June 1, 2002; 23(6): 906 - 912.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1983 by the Radiological Society of North America.